23 Result(s)
within
M. Fukuoka
English
Cancer Research
-
Article
Open AccessHuman equilibrative nucleoside transporter 1 and Notch3 can predict gemcitabine effects in patients with unresectable pancreatic cancer
Pancreatic ductal carcinoma (PDC) is one of the most lethal human carcinomas. Expression patterns of some genes may predict gemcitabine (GEM) treatment efficacy. We examined predictive indicators of survival i...
-
Article
Open AccessIdentification of thymidylate synthase as a potential therapeutic target for lung cancer
Thymidylate synthase (TS), a key enzyme in the de novo synthesis of thymidine, is an important chemotherapeutic target for malignant tumours including lung cancer. Although inhibition of TS has an antiproliferati...
-
Article
Open AccessMarked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs
Survivin, a member of the inhibitor of apoptosis protein family, is an attractive target for cancer therapy. We have now investigated the effects of the combination of YM155, a novel small-molecule inhibitor o...
-
Article
Open AccessMulticentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403)
The purpose of this study was to evaluate the efficacy of gefitinib and the feasibility of screening for epidermal growth factor receptor (EGFR) mutations among select patients with advanced non-small cell lung c...
-
Article
Open AccessEnhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status
The expression and activity of the epidermal growth factor receptor (EGFR) are determinants of radiosensitivity in several tumour types, including non-small cell lung cancer (NSCLC). However, little is known o...
-
Article
Open AccessThe novel microtubule-interfering agent TZT-1027 enhances the anticancer effect of radiation in vitro and in vivo
TZT-1027 is a novel anticancer agent that inhibits microtubule polymerisation and manifests potent antitumour activity in preclinical models. We have examined the effect of TZT-1027 on cell cycle progression a...
-
Article
Open AccessA phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B12 in Japanese patients with solid tumours
The purpose of this study was to determine the maximum tolerated dose (MTD) and recommended dose (RD) of pemetrexed with folate and vitamin B12 supplementation (FA/VB12) in Japanese patients with solid tumours an...
-
Article
Open AccessCombination phase I study of nedaplatin and gemcitabine for advanced non-small-cell lung cancer
To establish the toxicities and maximum tolerated dose (MTD) of nedaplatin with gemcitabine, and to observe their antitumour activity, we conducted a combination phase I study in advanced non-small-cell lung c...
-
Article
Open AccessRandomised phase II study of docetaxel/cisplatin vs docetaxel/irinotecan in advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group Study (WJTOG9803)
Docetaxel plus cisplatin and docetaxel plus irinotecan are active and well-tolerated chemotherapy regimens for advanced non-small-cell lung cancer (NSCLC). A randomised phase II study compared their efficacy a...
-
Article
Open AccessRandomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer
To determine a standard combination chemotherapy for patients with advanced non-small-cell lung cancer (NSCLC), we conducted a phase III trial of irinotecan (CPT-11) to test the hypotheses that CPT-11+cisplati...
-
Article
Open AccessDose-escalation study of weekly irinotecan and daily carboplatin with concurrent thoracic radiotherapy for unresectable stage III non-small cell lung cancer
Dose-escalation study was performed to evaluate the maximum tolerated dose, recommended dose and toxicity profile of weekly irinotecan with daily carboplatin and concurrent thoracic radiotherapy in patients wi...
-
Article
Phase I studies of nogitecan hydrochloride for Japanese
-
Article
Double-blind randomized control trial of the effect of recombinant human erythropoietin on chemotherapy-induced anemia in patients with non-small cell lung cancer
-
Article
Early phase II study of S-1, a new oral fluoropyrimidine, for advanced non-small-cell lung cancer
-
Article
Open AccessPhase I/II study of weekly irinotecan and concurrent radiation therapy for locally advanced non-small cell lung cancer
A study was undertaken to determine the maximum tolerated dose, the dose-limiting toxicities, and the response rate of irinotecan administered weekly with concurrent thoracic radiation therapy in patients with...
-
Article
Interleukin 6 is a cause of flu-like symptoms in treatment with a deoxycytidine analogue
The precise mechanism of fever and flu-like syndrome that occurs in treatment with deoxycytidine analogues remains unclear. This study demonstrated a strong correlation between plasma interleukin 6 levels and ...
-
Article
A phase II trial of combination of CPT-11 and cisplatin for advanced non-small-cell lung cancer
A phase I trial of the combination of irinotecan (CPT-11) with cisplatin in advanced non-small cell lung cancer (NSCLC) showed a very promising response rate of 54% in previously untreated NSCLC patients. This...
-
Article
Phase II trial of carboplatin plus oral etoposide for elderly patients with small-cell lung cancer
A phase II trial was conducted to evaluate the efficacy and toxicity of the Egorin's carboplatin dosing formula with 14-day oral etoposide in 38 elderly patients with small-cell lung cancer (SCLC). The overall...
-
Article
CODE chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer
Sixty-three patients with extensive-stage small-cell lung cancer were randomized to receive either cyclophosphamide, vincristine, doxorubicin and etoposide (CODE) alone or CODE plus recombinant human granulocy...
-
Article
Pro-gastrin-releasing peptide(31-98) as a tumour marker of small-cell lung cancer: comparative evaluation with neuron-specific enolase
We attempted to clarify whether serum levels of a carboxy-terminal fragment of ProGRP, ProGRP(31-98), could serve as a more accurate tumour marker in patients with SCLC than neuron-specific enolase (NSE). ProG...
